Dr. Albert Friesen reports

MEDICURE ANNOUNCES FDA PROVIDES COMPLETE APPROVAL TO ENROLL PATIENTS IN ITS PIVOTAL PHASE 3 TRIAL FOR TREATMENT OF RARE PEDIATRIC DISEASE

Medicure Inc. has received complete approval from the U.S. Food and Drug Administration to enroll patients in its pivotal phase 3 clinical trial to evaluate the use of its investigational product MC-1 for treatment of a rare pediatric disease called pyridox(am)ine 5'-phosphate oxidase (PNPO) deficiency. The study involves approximately 10 patients at sites in the United States and Australia, and the company is seeking marketing approval initially in those countries.

The U.S. FDA has granted both orphan drug designation and rare pediatric disease designation to MC-1 for the treatment of seizures associated with PNPO deficiency. Additionally, the European Medicines Agency (EMA) has granted orphan drug designation to MC-1 for the treatment of PNPO deficiency.

Under the Food and Drug Administration Safety and Innovation Act (FDASIA) passed into federal law in 2012, the FDA grants a rare pediatric disease designation for serious and life-threatening diseases in which the serious or life-threatening manifestations primarily affect individuals from birth to 18 years of age, with a prevalence of less than 200,000 people in the United States. If a new drug application (NDA) for MC-1 for patients with PNPO deficiency is approved, the company may be eligible to receive a priority review voucher (PRV) from the FDA, which can be redeemed to obtain priority review for any subsequent marketing application.

"MC-1 has the potential to become the first FDA-approved therapy for patients with PNPO deficiency. We sincerely thank all of the clinicians, patients and their families for participating in this study," said Dr. Albert D. Friesen, chief executive officer of Medicure and chair of its board of directors.

About Medicure Inc.

Medicure is a pharmaceutical company focused on the development and commercialization of therapies for the U.S. cardiovascular market. The present focus of the company is the marketing and distribution of Aggrastat (tirofiban hydrochloride) injection and Zypitamag (pitavastatin) tablets in the United States, where they are sold through the company's U.S. subsidiary, Medicure Pharma Inc. Medicure also operates Marley Drug, a pharmacy located in North Carolina that offers an extended supply drug program, serving all 50 states, Washington, D.C., and Puerto Rico. Marley Drug is committed to improving the health status of its patients and the communities it serves while reducing overall health care costs for employers and other health care consumers.

We seek Safe Harbor.